Your browser is no longer supported. Please, upgrade your browser.
Settings
SPPI Spectrum Pharmaceuticals, Inc. daily Stock Chart
SPPI [NASD]
Spectrum Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.22 Insider Own1.70% Shs Outstand111.78M Perf Week28.60%
Market Cap546.18M Forward P/E- EPS next Y-0.92 Insider Trans-4.36% Shs Float109.85M Perf Month16.16%
Income-136.20M PEG- EPS next Q-0.32 Inst Own52.20% Short Float5.82% Perf Quarter41.88%
Sales- P/S- EPS this Y0.20% Inst Trans-1.03% Short Ratio2.80 Perf Half Y39.82%
Book/sh1.38 P/B2.79 EPS next Y32.40% ROA-48.90% Target Price- Perf Year-49.41%
Cash/sh1.25 P/C3.07 EPS next 5Y- ROE-64.30% 52W Range1.74 - 10.57 Perf YTD5.63%
Dividend- P/FCF- EPS past 5Y-11.60% ROI- 52W High-63.62% Beta2.17
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low120.70% ATR0.31
Employees146 Current Ratio3.70 Sales Q/Q- Oper. Margin- RSI (14)59.52 Volatility9.40% 7.26%
OptionableYes Debt/Eq0.00 EPS Q/Q0.10% Profit Margin- Rel Volume1.61 Prev Close3.91
ShortableYes LT Debt/Eq0.00 EarningsAug 10 AMC Payout- Avg Volume2.28M Price3.85
Recom2.20 SMA2014.40% SMA5018.89% SMA200-8.70% Volume3,609,481 Change-1.66%
Dec-26-19Downgrade Guggenheim Buy → Neutral
Dec-26-19Downgrade Cantor Fitzgerald Overweight → Neutral $17 → $4
Nov-27-19Resumed B. Riley FBR Buy $18
Jul-11-19Initiated B. Riley FBR Buy $18
Mar-15-19Resumed Jefferies Buy $21
Nov-12-18Reiterated B. Riley FBR Buy $35 → $29
Dec-18-17Initiated B. Riley FBR, Inc. Buy $26
Oct-24-17Initiated Guggenheim Buy $32
Oct-19-17Reiterated H.C. Wainwright Buy $20 → $29
Oct-04-17Reiterated H.C. Wainwright Buy $14 → $20
Aug-16-17Resumed H.C. Wainwright Buy $14
Feb-10-17Resumed Jefferies Buy
Nov-05-15Reiterated RBC Capital Mkts Outperform $13 → $12
Aug-07-15Reiterated RBC Capital Mkts Outperform $12 → $13
Apr-02-15Initiated FBR Capital Outperform $9
Feb-23-15Downgrade ROTH Capital Buy → Neutral $15 → $7
Jul-15-14Upgrade R. F. Lafferty Sell → Neutral $7.50
Oct-07-13Initiated HC Wainwright Buy $15
May-29-13Initiated Burrill Institutional Research Mkt Outperform $12
Mar-13-13Reiterated RBC Capital Mkts Outperform $19 → $16
Aug-05-20 04:00PM  
Aug-03-20 07:00AM  
Jul-30-20 12:59PM  
07:00AM  
Jul-29-20 04:27PM  
Jul-28-20 12:00PM  
08:44AM  
03:32AM  
Jul-27-20 04:00PM  
Jul-16-20 09:00AM  
Jul-02-20 08:51AM  
Jun-25-20 11:23AM  
Jun-22-20 09:00AM  
Jun-21-20 10:39PM  
Jun-17-20 07:58PM  
Jun-16-20 07:00AM  
Jun-06-20 11:31AM  
Jun-05-20 03:37AM  
Jun-03-20 04:00PM  
May-27-20 07:00AM  
May-11-20 10:41AM  
May-08-20 11:00PM  
May-07-20 04:00PM  
May-01-20 07:00AM  
Apr-30-20 07:00AM  
Apr-28-20 07:00AM  
Apr-23-20 07:00AM  
Apr-21-20 07:00AM  
Apr-14-20 10:37AM  
Mar-28-20 11:30AM  
Mar-17-20 11:12AM  
07:00AM  
Mar-11-20 07:00AM  
Mar-03-20 07:00AM  
Mar-02-20 08:00AM  
Feb-28-20 08:46AM  
Feb-27-20 04:00PM  
Feb-20-20 09:27AM  
07:00AM  
Feb-06-20 07:00AM  
Jan-17-20 05:50PM  
Jan-15-20 01:39PM  
Dec-27-19 02:50PM  
08:05AM  
07:59AM  
06:56AM  
Dec-26-19 03:57PM  
02:09PM  
08:33AM  
07:55AM  
07:00AM  
05:57AM  
Dec-17-19 10:01AM  
Dec-11-19 03:27PM  
Dec-07-19 11:31AM  
Dec-05-19 06:32AM  
Nov-27-19 08:44AM  
Nov-16-19 09:40PM  
Nov-14-19 09:57AM  
Nov-08-19 10:08AM  
Nov-07-19 04:00PM  
Oct-31-19 07:00AM  
Oct-28-19 04:21PM  
Oct-24-19 04:00PM  
Oct-23-19 11:16AM  
Oct-04-19 07:00AM  
Oct-01-19 02:58PM  
Sep-27-19 11:03AM  
Sep-25-19 07:00AM  
Sep-20-19 11:54AM  
Sep-09-19 11:14AM  
Sep-07-19 09:30AM  
Sep-06-19 04:30PM  
Sep-02-19 11:40AM  
Aug-16-19 11:31AM  
Aug-12-19 03:03PM  
10:47AM  
Aug-08-19 10:57PM  
05:25PM  
04:00PM  
Aug-01-19 10:32AM  
Jul-22-19 07:00AM  
Jun-28-19 06:11PM  
Jun-23-19 04:56PM  
Jun-20-19 07:00AM  
Jun-17-19 09:54AM  
Jun-13-19 09:36AM  
Jun-08-19 09:30AM  
Jun-02-19 09:02AM  
May-29-19 07:00AM  
May-28-19 07:00AM  
May-21-19 01:33AM  
May-16-19 07:00AM  
May-10-19 05:55PM  
10:11AM  
05:05AM  
May-09-19 04:00PM  
07:00AM  
May-07-19 10:56AM  
May-02-19 07:00AM  
Spectrum Pharmaceuticals, Inc. develops and commercializes oncology and hematology drug products. The company offers KHAPZORY, a novel folate analog and the pharmacologically active levo-isomer of d, and 1-leucovorin; FOLOTYN, a folate analogue metabolic inhibitor for peripheral T-cell lymphoma (PTCL); ZEVALIN injection to treat non-Hodgkin's lymphoma; MARQIBO for adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia; BELEODAQ, a histone deacytelase, or HDAC, inhibitor for the treatment of patients with relapsed or refractory PTCL; and EVOMELA for use as a conditioning treatment prior to autologous stem cell transplant in multiple myeloma patients. It is also developing POZIOTINIB, a pan-HER inhibitor for non-small cell lung cancer tumors; ROLONTIS for chemotherapy-induced neutropenia; and QAPZOLA for non-muscle invasive bladder cancer. The company sells its drugs through group purchasing organizations, wholesalers, and directly to hospitals and cancer centers in the United States; and through distributors in Europe. It has a strategic partnership with Servier Canada, Inc.; licensing and development agreement with Cell Therapeutics, Inc.; license agreements with Merck & Cie AG, Medac Pharma, Inc., Sloan-Kettering Institute for Cancer Research, SRI International, Southern Research Institute, Medac Pharma, Inc., Cydex Pharmaceuticals, Inc., and Mundipharma International Corporation Limited; development and commercialization collaboration agreement with Allergan, Inc.; collaboration agreement with Nippon Kayaku Co., LTD.; licensing and collaboration agreement with Onxeo DK; and co-development and commercialization agreements with Hanmi Pharmaceutical Co. Ltd and The University of Texas MD Anderson Cancer Center. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was founded in 1987 and is headquartered in Henderson, Nevada.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
McGahan Keith MChief Legal OfficerJul 09Sale3.3613,88146,640249,313Jul 09 06:24 PM
McGahan Keith MChief Legal OfficerJun 24Sale3.2115,77350,631262,986Jun 25 05:01 PM
LEBEL FRANCOISChief Medical OfficerJun 23Sale3.354,16713,959292,729Jun 23 05:23 PM
LEBEL FRANCOISChief Medical OfficerJun 22Sale3.165,47417,320296,896Jun 23 05:23 PM
Ashton WilliamDirectorJun 22Sale3.255,00016,25041,666Jun 23 04:30 PM
McGahan Keith MChief Legal OfficerJun 22Sale3.253,0009,750278,759Jun 23 04:11 PM
McGahan Keith MChief Legal OfficerJun 19Sale3.133,45910,820281,759Jun 23 04:11 PM
Riga Thomas JEVP, COO & CCOMay 14Sale3.061,1253,443416,433May 15 06:40 PM
McGahan Keith MChief Legal OfficerMay 14Sale3.063501,071285,218May 15 06:35 PM
Riga Thomas JEVP, COO & CCOMay 13Sale3.252,0866,769417,558May 15 06:40 PM
McGahan Keith MChief Legal OfficerMay 13Sale3.254001,298285,568May 15 06:35 PM
LEBEL FRANCOISChief Medical OfficerApr 03Sale2.188541,862302,370Apr 06 04:28 PM
LEBEL FRANCOISChief Medical OfficerApr 02Sale2.171,2282,667303,224Apr 06 04:28 PM
Turgeon Joseph W.CEO & PresidentApr 01Sale2.232,5025,579691,134Apr 02 06:21 PM
Riga Thomas JEVP, COO & CCOApr 01Sale2.239382,092419,644Apr 02 06:19 PM
McGahan Keith MChief Legal OfficerApr 01Sale2.231,4673,271285,968Apr 02 06:18 PM
GUSTAFSON KURT AEVP & Chief Financial OfficerApr 01Sale2.233,1356,991360,830Apr 02 06:16 PM
Turgeon Joseph W.CEO & PresidentMar 31Sale2.314,0599,372693,636Apr 02 06:21 PM
Riga Thomas JEVP, COO & CCOMar 31Sale2.311,8544,281420,582Apr 02 06:19 PM
McGahan Keith MChief Legal OfficerMar 31Sale2.311,7864,124287,435Apr 02 06:18 PM
GUSTAFSON KURT AEVP & Chief Financial OfficerMar 31Sale2.314,3269,989363,965Apr 02 06:16 PM
McGahan Keith MChief Legal OfficerFeb 20Sale2.852,6677,601126,041Feb 21 08:06 PM
Riga Thomas JEVP, COO & CCOFeb 20Sale2.852,5007,125234,151Feb 21 07:52 PM
Turgeon Joseph W.CEO & PresidentFeb 20Sale2.853,75010,688415,268Feb 21 07:43 PM
GUSTAFSON KURT AEVP & Chief Financial OfficerFeb 20Sale2.853,3339,499205,111Feb 21 07:09 PM
McGahan Keith MChief Legal OfficerFeb 19Sale2.773,3419,258128,708Feb 21 08:06 PM
Riga Thomas JEVP, COO & CCOFeb 19Sale2.775,08514,091236,651Feb 21 07:52 PM
Turgeon Joseph W.CEO & PresidentFeb 19Sale2.776,26217,352419,018Feb 21 07:43 PM
GUSTAFSON KURT AEVP & Chief Financial OfficerFeb 19Sale2.774,73313,115208,444Feb 21 07:09 PM
McGahan Keith MChief Legal OfficerFeb 10Sale2.731,6674,551132,049Feb 11 05:53 PM
McGahan Keith MChief Legal OfficerFeb 07Sale2.782,0205,620133,716Feb 07 05:47 PM
GUSTAFSON KURT AEVP & Chief Financial OfficerJan 17Sale3.331,6215,398231,955Jan 17 06:24 PM
Turgeon Joseph W.CEO & PresidentJan 17Sale3.331,9446,474425,280Jan 17 06:14 PM
Riga Thomas JEVP, COO & CCOJan 17Sale3.265,00016,301241,678Jan 17 06:12 PM
GUSTAFSON KURT AEVP & Chief Financial OfficerJan 16Sale3.372,5228,492233,576Jan 17 06:24 PM
Turgeon Joseph W.CEO & PresidentJan 16Sale3.373,75312,636427,224Jan 17 06:14 PM
Riga Thomas JEVP, COO & CCOJan 16Sale3.3711,38138,320246,678Jan 17 06:12 PM
LEBEL FRANCOISChief Medical OfficerNov 06Sale8.166,96356,825113,970Nov 08 04:01 PM
McGahan Keith MChief Legal OfficerAug 12Sale7.772942,283135,543Aug 12 06:52 PM